There is a noticeable shift towards smart packaging technologies in the pharmaceutical blister packaging market. The trend of incorporating digital functions like tracking products using smartphones and reminding patients to take medication on...
China is upgrading its pharmaceutical industry to make drugs and healthcare more accessible. This is part of its plan to become more self-reliant through “new quality productive forces” driven by technical innovation and a supportive business...
India holds the biggest share in global generic medicine supply with 20 percent, producing 60,000 generic brands in 60 therapeutic categories. Products made in the country are sent to more than 200 countries worldwide, with Japan, Australia...
The dialysis machines sector in India makes up around 3% of the Asia Pacific market, with the majority of machines being imported, leading to increased expenses. GlobalData reported that the market is expected to reach $14 million by 2033 due to...
Continuous innovation and biopharmaceutical research are driving growth in the specialty pharmaceutical market. The industry's dedication to creating innovative treatment choices plays a crucial role in achieving better disease targeting with...
Shanghai Pharmaceuticals is the biggest drug importer in China and the second largest distributor of pharmaceuticals. Shanghai Pharmaceuticals generates $37 billion in total revenue and produces medications for cancer, diabetes, cardiovascular...
India’s pharma industry is on an impressive growth trajectory, expected to reach $65 billion by 2024 and to double to $130 billion by 2030. CPHI & P-MEC India exemplifies this growth by connecting global and domestic stakeholders to showcase...
Aptar is assisting Indian pharmaceutical firms in the launch of inhalers and nasal sprays for both local and export markets. Aptar is the top global supplier of inhalation devices, essential for administering medications used to manage respiratory...
The US investments mark the initial phase of significant actions aimed at supporting AstraZeneca's goal of reaching $80 billion in overall revenue by 2030, as outlined in May of this year. An essential aspect of our approach is hastening the...
Among the leading 10 therapies that account for over 90% of the Indian pharmaceutical market, price was the key factor in the expansion of the cardiac sector. The anti-hypertensive medications, comprising nearly 50% of the cardiac sector, are...
, CDSCO.jpg)
